Cargando…

Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome

INTRODUCTION: Insulin-like growth factor binding protein-3 (IGFBP-3) differentially modulates breast epithelial cell growth through insulin-like growth factor (IGF)-dependent and IGF-independent pathways and is a direct (IGF-independent) growth inhibitor as well as a mitogen that potentiates EGF (ep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vestey, Sarah B, Perks, Claire M, Sen, Chandan, Calder, Caroline J, Holly, Jeff MP, Winters, Zoe E
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064109/ https://www.ncbi.nlm.nih.gov/pubmed/15642160 http://dx.doi.org/10.1186/bcr963

Ejemplares similares

p14(ARF )expression in invasive breast cancers and ductal carcinoma in situ – relationships to p53 and Hdm2
por: Vestey, SB, et al.
Publicado: (2004)

Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor–binding protein 3?
por: Zielinska, Hanna A, et al.
Publicado: (2015)

Immunohistochemical categorisation of ductal carcinoma in situ of the breast
por: Meijnen, P, et al.
Publicado: (2008)

Hypoxia negates hyperglycaemia-induced chemo-resistance in breast cancer cells: the role of insulin-like growth factor binding protein 2
por: Al Qahtani, Athba, et al.
Publicado: (2017)

Insulin-like growth factor binding protein-2 alters the sensitivity of breast cancer cells to chemotherapy
por: Foulstone, EJ, et al.
Publicado: (2010)

Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast
por: Perez, Amanda Arantes, et al.
Publicado: (2013)

Immunohistochemical Expression of Nanog and Its Relation with Clinicopathologic Characteristics in Breast Ductal Carcinoma
por: Saravi, Omid Emadian, et al.
Publicado: (2019)

Insulin-like growth factor binding protein 3 modulates epidermal growth factor (EGF)-induced growth of breast epithelial cells by altering EGF receptor internalization
por: Dennison, GJ, et al.
Publicado: (2008)

Hyperglycemia Promotes TMPRSS2-ERG Gene Fusion in Prostate Cancer Cells via Upregulating Insulin-Like Growth Factor-Binding Protein-2
por: Holly, Jeff M. P., et al.
Publicado: (2017)

The Neglected Insulin: IGF-II, a Metabolic Regulator with Implications for Diabetes, Obesity, and Cancer
por: Holly, Jeff M. P., et al.
Publicado: (2019)

Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ
por: Liu, Yang, et al.
Publicado: (2023)

Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.
por: Luqmani, Y. A., et al.
Publicado: (1993)

Insulin-like growth factors: Ligands, binding proteins, and receptors
por: LeRoith, Derek, et al.
Publicado: (2021)

Tubular Carcinoma of the Breast: Clinicopathologic Features and Survival Outcome Compared with Ductal Carcinoma In Situ
por: Min, Yejin, et al.
Publicado: (2013)

Clinicopathological Characteristics of Breast Ductal Carcinoma In Situ: An Analysis of Chinese Population of 617 Patients
por: Mao, Guangmin, et al.
Publicado: (2021)

Microinvasive Carcinoma versus Ductal Carcinoma In Situ: A Comparison of Clinicopathological Features and Clinical Outcomes
por: Kim, Milim, et al.
Publicado: (2018)

The role of MRI and clinicopathologic features in predicting the invasive component of biopsy-confirmed ductal carcinoma in situ
por: Yoon, Ga Young, et al.
Publicado: (2020)

Associations of clinicopathological factors with local treatment and survival outcome in elderly patients with ductal carcinoma in situ
por: Zhang, Xu, et al.
Publicado: (2023)

Clinicopathological characteristics, treatments, and prognosis of breast ductal carcinoma in situ with microinvasion: A narrative review
por: Song, Ge, et al.
Publicado: (2022)

Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment
por: Takagi, K, et al.
Publicado: (2013)

Clinicopathological predictive factors for ipsilateral and contralateral events following initial surgery to treat ductal carcinoma in situ
por: Tamura, Nobuko, et al.
Publicado: (2015)

Trends and clinicopathological predictors of axillary evaluation in ductal carcinoma in situ patients treated with breast‐conserving therapy
por: Huang, Nai‐si, et al.
Publicado: (2017)

Elucidating the novel BRCA1 function as a non-genomic metabolic restraint in ER-positive breast cancer cell lines
por: Koobotse, Moses, et al.
Publicado: (2018)

Perineural Invasion and TAMs in Pancreatic Ductal Adenocarcinomas: Review of the Original Pathology Reports Using Immunohistochemical Enhancement and Relationships with Clinicopathological Features
por: Zeng, Linjuan, et al.
Publicado: (2014)

IGFBP-2 acts as a tumour suppressor and plays a role in determining chemosensitivity in bladder cancer cells
por: Tang, Zhen, et al.
Publicado: (2019)

Insulin Receptor Isoform Variations in Prostate Cancer Cells
por: Perks, Claire M., et al.
Publicado: (2016)

Expression of e-cadherin, n-cadherin and snail and their correlation with clinicopathological variants: an immunohistochemical study of 132 invasive ductal breast carcinomas in Egypt
por: ElMoneim, Hanan Mohamed Abd, et al.
Publicado: (2011)

Recurrence in Oral Premalignancy: Clinicopathologic and Immunohistochemical Analysis
por: Georgaki, Maria, et al.
Publicado: (2021)

Ductal adenocarcinoma of the prostate: immunohistochemical findings and clinical significance
por: Sha, Jianjun, et al.
Publicado: (2013)

Ductal carcinoma in situ (DCIS)
por: Holland, R
Publicado: (2002)

Ductal Carcinoma In Situ of the Breast
por: Lee, Richard J., et al.
Publicado: (2012)

Breast Ductal Carcinoma In Situ
por: Sacchini, Virgilio, et al.
Publicado: (2012)

Comparison of clinicopathological characteristics and prognosis among patients with pure invasive ductal carcinoma, invasive ductal carcinoma coexisted with invasive micropapillary carcinoma, and invasive ductal carcinoma coexisted with ductal carcinoma in situ: A retrospective cohort study
por: Guan, Xin, et al.
Publicado: (2020)

Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study
por: Tanaka, Kiyo, et al.
Publicado: (2021)

Clinicopathological and Immunohistochemical Characterisation of Gastric Schwannomas in 29 Cases
por: Zheng, Lijun, et al.
Publicado: (2014)

Epithelial ovarian tumors: Clinicopathological correlation and immunohistochemical study
por: Naik, Pooja S., et al.
Publicado: (2015)

Cutaneous pseudolymphoma: A clinicopathological study and immunohistochemical patterns
por: Sari Aslani, Fatemeh, et al.
Publicado: (2021)

Male Breast Cancer: Clinicopathological, Immunohistochemical and Radiological Study
por: Hasbay, Bermal, et al.
Publicado: (2020)

Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer
por: Wei, Zhang, et al.
Publicado: (2012)

Intrinsic, Pro-Apoptotic Effects of IGFBP-3 on Breast Cancer Cells are Reversible: Involvement of PKA, Rho, and Ceramide
por: Perks, Claire M., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_e9pj39r7h1uj7fi8ftseedipdl